Tislelizumab
AACR-ADOPT-GEA
Phase 2 small_molecule active
Quick answer
Tislelizumab for Gastroesophageal Adenocarcinoma is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Gastroesophageal Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active